Quick Comparison

Emoxypine (Mexidol)NMN (Nicotinamide Mononucleotide)
Half-Life2-2.6 hours2-3 minutes in blood (rapidly converted to NAD+). NAD+ half-life: 1-2 hours in tissue
Typical DosageStandard: 125-375 mg daily in 2-3 divided doses. Commonly 125 mg twice daily. Take with food. Effects are noticeable within 30-60 minutes. Russian clinical practice uses 4-6 week courses.Standard: 250-1000 mg daily. Sublingual may improve bioavailability by bypassing first-pass metabolism. Take in the morning — NAD+ follows circadian rhythm and morning supplementation aligns with natural peaks. Effects build over weeks.
AdministrationOral (tablets). Also available as IV/IM injection in clinical settings. Mexidol is the brand name.Oral (capsules, powder, sublingual). Sublingual may improve bioavailability. Store in cool, dry place.
Research Papers10 papers10 papers
Categories

Mechanism of Action

Emoxypine (Mexidol)

Emoxypine (2-ethyl-6-methyl-3-hydroxypyridine succinate) has a 3-hydroxypyridine structure similar to vitamin B6 (pyridoxine). It is one of the most potent inhibitors of lipid peroxidation in brain tissue — it scavenges hydroxyl radicals and peroxyl radicals, inhibits Fe2+-induced lipid peroxidation, and may chelate transition metals. It modulates the GABA-benzodiazepine receptor complex (GABA-A), enhancing GABAergic transmission through positive allosteric modulation — possibly at a site distinct from the classical benzodiazepine binding site, explaining the lack of sedation and tolerance. It improves mitochondrial function (Complex I protection, membrane stabilization), stabilizes cell membranes (reducing fluidity changes during oxidative stress), and enhances cerebral microcirculation (possibly via nitric oxide or prostaglandin modulation). The anxiolytic mechanism may involve partial agonism or different subunit selectivity.

NMN (Nicotinamide Mononucleotide)

NMN is transported into cells via the Slc12a8 transporter (highly expressed in the small intestine and brain) and converted to NAD+ by nicotinamide mononucleotide adenylyltransferases (NMNAT1 in the nucleus, NMNAT2 in axons/Golgi, NMNAT3 in mitochondria). Elevated NAD+ activates the sirtuin family of NAD+-dependent protein deacetylases: SIRT1 deacetylates PGC-1alpha to promote mitochondrial biogenesis, SIRT3 activates superoxide dismutase 2 (SOD2) and isocitrate dehydrogenase 2 (IDH2) for mitochondrial antioxidant defense, and SIRT6 promotes base excision repair of oxidative DNA damage. NAD+ is also consumed by poly(ADP-ribose) polymerases (PARP1/2) during DNA repair — age-related NAD+ depletion impairs PARP function, allowing DNA damage accumulation. In neurons, NAD+ is required for glycolysis (GAPDH cofactor), the TCA cycle, and Complex I of the electron transport chain, directly fueling the enormous ATP demands of synaptic transmission. NAD+ decline with aging (approximately 50% reduction between ages 40-60) reduces all of these processes simultaneously, creating a cascade of mitochondrial dysfunction, impaired DNA repair, and neuroinflammation that NMN supplementation aims to reverse.

Risks & Safety

Emoxypine (Mexidol)

Common

Mild nausea, drowsiness, dry mouth.

Serious

Limited Western safety data. Allergic reactions reported.

Rare

Elevated blood pressure, emotional lability.

NMN (Nicotinamide Mononucleotide)

Common

Mild flushing, nausea, headache initially.

Serious

Long-term human safety data still limited (first human trials completed 2020-2023). Theoretical concern about promoting cancer growth in existing tumors (NAD+ fuels fast-growing cells).

Rare

Insomnia if taken late.

Full Profiles